Tesamorelin

Origin & Classification

Tesamorelin is a 44-amino-acid peptide analog of endogenous growth hormone-releasing hormone (GHRH). It is engineered by substituting the N-terminal peptide with modifications that confer resistance to dipeptidyl peptidase-IV and by adding a trans-3-hexenyl modification to enhance stability. The peptide is produced via recombinant DNA technology or solid-phase synthesis and belongs to the class of GHRH analogs with prolonged activity.

Mechanism & Research Context

Tesamorelin binds to the GHRH receptor on pituitary somatotrophs, stimulating adenylate cyclase, increasing cAMP levels, and promoting growth hormone secretion. Researchers use Tesamorelin to investigate regulation of the growth hormone-insulin-like growth factor axis, receptor desensitization, and feedback mechanisms involving somatostatin and IGF-1. Studies also examine how prolonged activation of the GHRH receptor influences metabolic pathways, body composition, and gene expression in tissues responsive to growth hormone. Tesamorelin provides a tool to explore endocrine regulation and the downstream signaling cascades including JAK/STAT, PI3K/AKT, and MAPK in a controlled research setting.

Composition & Quality

Tesamorelin is supplied as a lyophilized powder with purity typically above 95 %, as measured by HPLC and mass spectrometry. It is manufactured under GMP-aligned standards, with purification, sterile filtration, and quality control processes to ensure identity and absence of contaminants. Stability studies support storage of the lyophilized peptide at low temperature, and reconstituted solutions should be used promptly to maintain peptide integrity. Certificates of analysis provide details on sequence, purity, and recommended storage conditions.

Summary & Unified Disclaimer

This description summarizes the scientific context of the molecule. It is provided for educational and research discussion purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and no medical or consumption claims are made.